<DOC>
	<DOCNO>NCT02587520</DOCNO>
	<brief_summary>This dose formulation range study ass safety immunogenicity SP0173 healthy adolescent , adult , old adult US . Primary Objective - To describe safety profile SP0173 investigational formulation . Observational Objective : - To describe immunogenicity SP0173 investigational formulation .</brief_summary>
	<brief_title>Study Tetanus Toxoid , Reduced Diphtheria Toxoid , Acellular Pertussis Vaccine Adsorbed Healthy Subjects</brief_title>
	<detailed_description>All subject receive single dose vaccine , assess immunogenicity baseline ( pre-vaccination ) 30 day post-vaccination . They also monitor safety day vaccination Day 180 post-vaccination .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 10 18 year , 19 64 year , ≥ 65 year day inclusion Informed consent form sign dated subject , assent form sign date subject inform consent form sign dated parent/guardian Subject subject parent/guardian able attend schedule visit comply study procedure . Subject pregnant , lactating , childbearing potential , ( consider nonchildbearing potential , female must premenarche postmenopausal least 1 year ) surgically sterile , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination Participation time study enrollment plan participation present study period another clinical trial investigate vaccine , drug , medical device , medical procedure Received vaccine 4 week precede trial vaccination plan receipt vaccine Visit 1 Visit 2 Known suspect receipt tetanus toxoid , reduce diphtheria toxoid , Acellular pertussis ( Tdap ) vaccine Tdapcontaining vaccine point time , receipt tetanus diphtheria contain vaccine precede 5 year Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy History diphtheria , tetanus , pertussis infection ( confirm either serologically microbiologically ) Known suspect systemic hypersensitivity vaccine component history lifethreatening reaction study vaccine vaccine contain substance Laboratoryconfirmed / selfreported thrombocytopenia bleed disorder contraindicate intramuscular vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination History encephalopathy ( e.g. , coma , decrease level consciousness , prolonged seizure ) attributable another identifiable cause within 7 day administration previous dose diphtheria tetanus toxoid pertussis ( DTP ) , diphtheria tetanus toxoid acellular pertussis ( DTaP ) vaccine Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction Chronic illness stage might interfere trial conduct completion Moderate severe acute illness/infection day vaccination febrile illness ( temperature ≥ 100.4°F ) Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Tetanus</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Pertussis</keyword>
	<keyword>SP0173</keyword>
	<keyword>Tdap vaccine</keyword>
</DOC>